In February 2010, a quadrivalent conjugate vaccine (Menveo; Novartis Vaccines and Diagnostics) was approved by the US FDA to prevent invasive meningococcal disease caused by Neisseria meningitidis ...

In England and Wales, MCC vaccine programs resulted in substantial herd immunity, as shown by reductions in serogroup C carriage prevalence and serogroup C disease in unvaccinated individuals.